Medical cannabis company MGC Pharma
(ASX:MXC) has announced the launch of MGC Nutraceuticals.
The new product line offers a range of premium vegan products for the high-end dietary supplement market.
The company says the global nutraceutical market was valued at about $383 billion US dollars in 2016 and is expected to grow to over $500 billion by 2022
The European based business says the new range leverages the company’s existing medicinal cannabis IP.
Shares in MGC Pharma
(ASX:MXC) are trading 3.19 per cent higher to 10 cents.
